Cardiac Drug Safety in Transitions: Clinical Evidence, Mechanisms, and Practical Implications

Abstract

Transitions of care represent critical periods during which patients with cardiovascular diseases are at heightened risk for medication errors, adverse drug events, and therapeutic failures. This review provides an in-depth analysis of cardiac drug safety issues that arise during transitions, including hospital admissions, transfers, and discharges. We synthesize recent evidence on epidemiology, mechanisms underlying drug-related harm, risk factors, and guideline-based strategies for optimizing safety. The article highlights emerging therapies, clinical pearls, and practical recommendations to improve outcomes and minimize risks during care transitions in cardiac patients.

Introduction

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, necessitating complex pharmacotherapy regimens that often require adjustment during transitions of care. Such transitions including admission, inter-facility transfer, and discharge are periods of vulnerability wherein medication discrepancies, omissions, and interactions frequently occur. Ensuring the safety of cardiac drug therapy during these transitions is crucial, as mismanagement can result in serious adverse events, rehospitalizations, and increased healthcare costs. This review aims to equip clinicians with current evidence, mechanistic insights, and practical guidance on optimizing cardiac drug safety during transitions.

Epidemiology / Disease Burden

Medication errors are common during transitions of care, with studies indicating that up to 70% of hospitalized patients experience at least one medication discrepancy during admission or discharge. Cardiovascular medications such as antithrombotics, beta-blockers, ACE inhibitors, and antiarrhythmics are frequently implicated due to their narrow therapeutic indices and high potential for interactions. Adverse drug events (ADEs) during transitions contribute significantly to readmissions, with cardiac drugs accounting for a disproportionate share of severe events. The burden is especially pronounced in older adults and those with multimorbidity, polypharmacy, and frequent care transitions.

Pathophysiology

The pathophysiological basis for increased drug-related harm during transitions centers on abrupt changes in pharmacokinetics and pharmacodynamics, altered organ function, and loss of continuity in medication management. For example, renal or hepatic dysfunction common in acute cardiac decompensation can alter drug metabolism and excretion, heightening toxicity risk. Inadequate communication between providers may result in duplication, omission, or inappropriate modification of essential cardiac medications, further compounding risk. Drug-drug and drug-disease interactions are particularly relevant in cardiac patients due to frequent co-prescribing of agents with opposing or synergistic effects on hemodynamics and electrophysiology.

Risk Factors

Numerous risk factors predispose cardiac patients to medication-related harm during transitions. These include advanced age, cognitive impairment, low health literacy, polypharmacy, and the presence of comorbidities such as chronic kidney disease or liver dysfunction. Patients discharged after acute coronary syndromes, heart failure exacerbation, or cardiac surgery are particularly susceptible due to rapid changes in drug regimens and physiologic status. Inadequate medication reconciliation, lack of standardized protocols, and poor interprofessional communication further amplify risk.

Clinical Features

Clinical manifestations of drug-related harm in cardiac transitions range from asymptomatic laboratory abnormalities to life-threatening arrhythmias, bleeding, hypotension, or organ dysfunction. Examples include rebound angina following abrupt beta-blocker discontinuation, digoxin toxicity in the context of renal impairment, and bleeding events with mismanaged antithrombotic therapy. Many ADEs may present nonspecifically such as fatigue, confusion, or falls necessitating a high index of suspicion during transitions.

Diagnosis

Timely diagnosis of cardiac drug-related ADEs during transitions relies on meticulous medication reconciliation, thorough clinical assessment, and targeted laboratory or electrocardiographic studies. In practice, a structured approach involves reviewing the entire medication history, identifying discrepancies, and assessing for new or worsening symptoms. Laboratory monitoring of renal and hepatic function, serum drug levels (where appropriate), and assessment for QT prolongation or arrhythmias is essential in high-risk scenarios. Interprofessional collaboration particularly involving pharmacists enhances diagnostic accuracy.

Treatment & Management

Effective management of cardiac drug safety during transitions centers on prevention, early identification, and prompt intervention. Key strategies include comprehensive medication reconciliation at every transition point, use of standardized checklists, clear communication of medication changes, and patient/caregiver education. When ADEs are suspected or confirmed, management involves cessation or adjustment of the offending agent, supportive care, and, where indicated, administration of specific antidotes (e.g., vitamin K for warfarin overdose). Close post-discharge follow-up and monitoring are critical to ensuring ongoing safety and therapeutic efficacy.

Recent Advances / Emerging Therapies

Recent advances in health information technology such as electronic health records (EHRs) with integrated clinical decision support have shown promise in reducing medication errors and improving outcomes. Emerging models of transitional care, including pharmacist-led medication reconciliation and telemedicine-supported follow-up, have demonstrated reductions in ADEs and readmissions in cardiac populations. Novel oral anticoagulants and newer antiplatelet agents, with more predictable pharmacokinetics and fewer interactions, may further enhance safety during transitions, though careful selection and monitoring remain essential.

Guideline Recommendations

Multiple professional societies including the American Heart Association, American College of Cardiology, and Institute for Healthcare Improvement emphasize the importance of structured medication reconciliation at every transition. Guidelines advocate for multidisciplinary approaches, patient-centered education, and systematic communication between hospital and outpatient providers. Specific recommendations include verification of medication lists, assessment of adherence barriers, and individualized risk stratification to guide monitoring and follow-up intensity. Incorporating clinical pharmacists into the care team is strongly recommended to optimize cardiac drug safety.

Conclusion

Transitions of care present significant challenges and opportunities for optimizing cardiac drug safety. By understanding the epidemiology, mechanisms, risk factors, and clinical manifestations of drug-related harm, clinicians can implement evidence-based strategies to reduce errors and improve patient outcomes. Recent advances in technology and care models offer additional tools to enhance safety. Ongoing education, interprofessional collaboration, and adherence to guideline-based protocols are essential to safeguarding cardiovascular patients during these vulnerable periods.